January 6, 2022
Ono Pharmaceutical said on January 5 that its PD-1 inhibitor Opdivo (nivolumab) obtained an additional indication in Taiwan as an adjuvant therapy for certain patients with esophageal cancer and gastroesophageal junction cancer. The approval granted on December 29 is for...read more